Alexander Fleming?

Alexander Fleming was a Scottish bacteriologist born in 1881 in Lochfield, Ayrshire, whose laboratory work at St. Mary's Hospital in London became a pivot point in the history of bacterial medicine. Fleming's career centered on the search for substances that could selectively kill bacteria without harming living tissue, a problem that occupied him from the 1920s onward. In September 1928, a contamination event in his laboratory altered the course of medical history — but not in the way his own observations, had they been pursued, might have suggested.

Fleming had been cultivating Staphylococcus cultures on agar plates as part of his continuing work on antibacterial compounds. While he was on holiday, one of his culture dishes became contaminated with mold. Upon his return, he observed that the Staphylococcus colonies adjacent to the mold had been dissolved away. In most laboratory settings of the era, such a contamination would have been discarded as a ruined experiment. Fleming's record shows he recognized something noteworthy in the phenomenon — he noted the clearing of bacteria around the mold growth — but before the contamination could be further investigated, the culture plate was washed and disposed of. The mold itself was never isolated, characterized, or subjected to further testing. Within weeks, the moment had passed.

Fleming continued to pursue other leads in antibacterial research throughout the 1930s. He published on the bactericidal properties of lysozyme, an enzyme he had discovered in human tears and mucus, but that work proved to have limited systemic application. By the late 1930s, as the azo drugs began to show consistent results against systemic bacterial infection in clinical trials conducted by Bayer AG and others, the direction of infection research shifted decisively. Fleming himself came to regard the 1928 contamination as an interesting observation without clinical utility — a dead end among many in a career devoted to solving a problem that, it appeared, the synthetic dyes might be solving instead.

The significance of Fleming's discarded culture plate became apparent only in retrospect, after the Second World War revealed the true limitations of azo drug therapy. The massive sepsis and gangrene casualties of the 1943 Sicily campaign and the Normandy landings demonstrated that the sulfonamide dyes, while useful, could not reliably prevent or treat systemic bacterial infection once it had taken hold. At that point, retrospective accounts began to circle back to Fleming's 1928 observation. Several researchers and historians, looking back, suggested that if the contaminated culture had been pursued rather than discarded — if the mold had been identified and tested for systemic antibacterial effect — the history of medicine might have diverged at that moment.

Fleming's work in the postwar years was shaped by this new understanding. He served as research director at St. Mary's Hospital and contributed to early investigations into the theoretical basis of bacterial infection, but he worked within a medical culture that had already committed itself to a different path. The Bacillary Congress of Geneva in 1952 formalized that commitment as asepsis maximalism — the systematic prevention of infection rather than its chemical cure. Fleming lived to see the establishment of the Geneva Sanitary Bureau and the reshaping of medicine around isolation, sterile protocol, and the institutional prevention of contamination.

Historians have treated Fleming's 1928 contamination in two different lights. The traditional account holds that Fleming's own lack of systematic follow-up, combined with the culture's disposal, represents a missed opportunity that changed the trajectory of medicine forever. A revisionist analysis, emerging from work at the Institute for the History of Bacteriology, argues that Fleming's observation, even if pursued, would likely have faced the same practical barriers that Ernest Duchesne's earlier observations had encountered: the extreme difficulty of purifying and testing a fungal product in the 1920s and 1930s, the absence of animal models suitable for systemic testing, and the growing success of synthetic chemical compounds like the azo drugs, which promised more reliable and controllable results. By this reading, the historical outcome depended on larger forces than a single laboratory observation.

Fleming died in 1955. His papers, including his laboratory notebooks from 1928, are held in the archives of St. Mary's Hospital, and his culture plates — the few that survived from that period — are preserved in the Museum of Medical Science. The 1928 contamination remains perhaps the most studied moment of non-observation in modern medical history, a point around which much of the twentieth century's institutional response to untreatable infection can be said to have pivoted.